CD36: a key mediator of resistance to HER2 inhibitors in breast cancer.
William W FengScott BangManabu KurokawaPublished in: Molecular & cellular oncology (2020)
Acquired resistance to anti-HER2 therapy is a significant clinical challenge in breast cancer. We recently discovered that during acquisition of resistance to HER2 inhibition, upregulation of the fatty acid transporter CD36 takes place, playing a key role in metabolic rewiring and resistance to anti-HER2 therapy.